RT Journal Article
SR Electronic
T1 Plasma Proteome Variation and its Genetic Determinants in Children and Adolescents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.31.23287853
DO 10.1101/2023.03.31.23287853
A1 Niu, Lili
A1 Stinson, Sara Elizabeth
A1 Holm, Louise Aas
A1 Vonsild Lund, Morten Asp
A1 Fonvig, Cilius Esmann
A1 Cobuccio, Leonardo
A1 Meisner, Jonas
A1 Bæk Juel, Helene
A1 Thiele, Maja
A1 Krag, Aleksander
A1 Holm, Jens-Christian
A1 Rasmussen, Simon
A1 Hansen, Torben
A1 Mann, Matthias
YR 2023
UL http://medrxiv.org/content/early/2023/03/31/2023.03.31.23287853.abstract
AB The levels of specific proteins in human blood are the most commonly used indicators of potential health-related problems1. Understanding the genetic and other determinants of the human plasma proteome can aid in biomarker research and drug development. Diverse factors including genetics, age, sex, body mass index (BMI), growth and development including puberty can affect the circulating levels of proteins2–5. Affinity-based proteomics can infer the relationship between blood protein levels and these factors at a large scale6–10. Compared to these methods, mass spectrometry (MS)-based proteomics provides much higher specificity of identification and quantification11–13, but existing studies are limited by small sample sizes or low numbers of quantified proteins14–17. Here we aim to elucidate to which extent genomic variation affects plasma protein levels across diverse age ranges and cohort characteristics. Employing a streamlined and highly quantitative MS-based plasma proteomics workflow, we measured the plasma proteome of 2,147 children and adolescents. Levels of 90% of these proteins were significantly associated with age, sex, BMI or genetics. More than 1,000 protein quantitative trait loci (pQTLs) – a third of which were novel – regulated protein levels between a few percent and up to 30-fold. These replicated excellently in an independent cohort of 558 adults, with highly concordant effect sizes (Pearson’s r > 0.97). We developed a framework to eliminate artefactual pQTLs due to protein-altering variants, paving the way for large-scale interrogation of pQTLs using MS-based proteomics. Our data reveal unexpectedly extensive genetic impacts on plasma protein levels, consistent from childhood into adulthood. These findings have implications for biomarker research and drug development.HighlightsFirst large-scale proteome-wide and genome-wide association study in children and adolescentsMS-based proteomics achieves very high specificity and quantitative accuracyRobust plasma protein trajectories during development predict age and body mass indexLargest set of pQTLs for plasma proteome by MS-based proteomicspQTLs are highly replicable between children and adultsLarge-scale pQTL identification enables generic drug target validationCompeting Interest StatementM.M. is an indirect investor in Evosep.Funding StatementThis study was funded by the Novo Nordisk Foundation for the Clinical Proteomics Group (grant no. NNF15CC0001 to M.M.), the Challenge Program (grant no. NNF15OC0016692 to the MicrobLiver consortium), the Innovation Fund Denmark (grant no. 0603-00484B to T.H.), and the Novo Nordisk Foundation (grant no. NNF15OC0016544), while the European Union Horizon 2020 research and innovation program (grant no. 668031 to the GALAXY consortium) funded the GALAXY cohorts in the ALD study. Additionally, L.N. and S.R. received support from the Novo Nordisk Foundation (grant no. NNF14CC0001 and NNF21SA0072102 to S.R.), M.T. from the Novo Nordisk Foundation (grant no. NNF20OC0059393), C.E.F. received support from the BRIDGE - Translational Excellence Program (grant no. NNF18SA0034956) and the Region Zealand Health and Medical Research Foundation (grant no. R32-A1191).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee for the Region Zealand and Region of Southern Denmark in Denmark gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets produced in the present study are available upon reasonable request to the authors. All analysis results are available as supplementary tables. Searchable results are available online at proteomevariation.org https://ftp.ebi.ac.uk/pub/databases/reference_proteomes https://www.ebi.ac.uk/gwas/docs/file-downloads https://grch37.ensembl.org/info/data/biomart/index.html